Jennison Associates LLC I Mab Transaction History

Jennison Associates LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$45.28 - $74.5 $7.54 Million - $12.4 Million	-166,485 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$57.18 - $84.43 $215,854 - $318,723	-3,775 Reduced 2.22%	166,485 $12.1 Million
Q1 2021 May 11, 2021	BUY	$44.38 - $63.97 $7.56 Million - $10.9 Million	170,260 New	170,260 $8.25 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.